Kardiorespirator tadqiqotlar jurnali. Maxsus son. 2022
Subject of the article
METFORMINNING MASTOPATIYA KECHICHIGA TASIRI (670-673)
Authors
Saidiganxodja I.I., Otabek S.Y., Tojiboeva D.M., Sultanov Sh.B.
Institution
Toshkent pediatriya tibbiyot instituti, Toshkent tibbiyot akademiyasi,Toshkent tibbiyot akademiyasi Urganch filiali assistenti
Abstract
Mastopatiya – ayollarning eng keng tarqalgan kasalligi bo’lib, mammologiyadagi kasalliklar oqimining 90% ini tashkil etadi. Fibroz kistoz mastopatiya etiologiyasi oxirigacha aniqlanmagan bo’lib, lekin ko’p o’rganilgan xavf omillariga endokrin buzilishlar, xususan insulinorezistentlik va qalqonsimon bez kasalliklari kiradi
Key words
mastopatiya, mastalgiya, inslinorezistentlik, metformin
Literature
1. Sadaf Alipour, Hadith Rastad Metformin in the management of fibrocystic breast disease: a placebocontrolled randomized clinical tria. DARU Journal of Pharmaceutical Sciences (2021) 29:389–396. 2. Sadaf Alipour, Mahboubeh Abedi. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial BMC Endocrine Disorders (2021) 21:169 https:G’G’doi.orgG’10.1186G’s12902-021-00824-4. 3. Kats I.P., Pavlova E.A., Ordiyants I.M. Rol geneticheskix faktorov i immunno’x narusheniy v razvitii dobrokachestvenno’x zabolevaniy molochno’x jelez G’G’materialo’ II Mejdistsiplinarnogo foruma «Meditsina molochnoy jelezo’». M.: Mediabyuro Status prezens, 2012. S. 27–31. 4. Figueroa JD, et al. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. Breast Cancer Research & Treatment 2016;159(1):163-172. 5. Musina E.V., Kogan I.Yu. Vozmojnosti primeneniya biguanidov pri fibrozno-kistoznoy bolezni u jenhin reproduktivnogo vozrasta G’G’ Jurnal akusherstva i jenskix bolezney. - 2019. - T. 68. - № 3. - S. 35 - 40. 6. Silvera SAN, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Research and Treatment. 2007;110(3):397 - 409. 7. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103- 1123. 8. Gonzalez - Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16(6):1695-1700. 9. Boyd DB. Insulin and Cancer. Integr Cancer Ther. 2016;2(4): 315-329. 10. Tarique M. A Prospective Study on Prevalence of Hyperprolactinemia & Hypothyroidism in Benign Breast Diseases. Int Arch BioMed Clin Res. 2019;5(1):18 – 19. 11. Gunter MJ, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48–60. AbstractG’FREE Full TextGoogle Scholar. 12. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591. 13. Catsburg C., Gunter M.J., Chen C. et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014;74(12):3248—58. 14. Chelsea Catsburg, Marc J. Gunter, et al. Insulin, Estrogen, Inflammatory Markers, and Risk of Benign Proliferative Breast Disease Cancer Res; 74(12) June 15, 2014 DOI: 10.1158G’0008-5472.CAN-13- 3514. 15. Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647. 16. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31- 43. 17. Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647. 18. Tu C, Ren X, He J, Zhang C, Chen R, Wang W, Li Z. The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers. J Cancer. 2019;10(24):5992-6002. [PMC free article] [PubMed]. 19. Sonia Del Barco Metformin: Multi-faceted protection against cancer Oncotarget 2011; 2: 896 – 917.